“It makes me nauseous going home at night because it makes me feel like I’m deciding, with this limited resource, who should get it,” Dr. Christian Ramers, an infectious disease specialist at Family Health Centers of San Diego, a network of clinics for low-income patients, told the newspaper.
Ramers’ clinics have had to turn away most — about 90% — of the hundreds of people who call every day seeking COVID treatments they’re eligible to get, he added.
“It is devastating to tell these patients, ‘Sorry, we can’t do anything for you, we have to save this drug only for our most severely immunocompromised,'” Erin McCreary, an infectious diseases pharmacist at the University of Pittsburgh Medical Center, told the Times.
Monoclonal antibodies, which are administered intravenously, have been the primary treatment for newly infected patients. The two most common types, however, don’t appear to keep Omicron at bay.
The one monoclonal antibody that is effective against Omicron, made by GlaxoSmithKline and Vir Biotechnology, is in limited supply. The federal government has ordered only about 450,000 treatment courses, the Times reported. The United States did not immediately order supplies of that treatment when it was authorized last May because it already had a large supply of other antibody treatments.
Meanwhile, Paxlovid is a new, powerful antiviral pill from Pfizer that the U.S. Food and Drug Administration authorized two weeks ago. But supplies of that drug are also scarce. Supplies of Paxlovid won’t be plentiful until April, even though the Biden administration doubled its order this week. Large quantities of the treatment are only now becoming available because it takes eight months to produce the pills, the Times reported.